Sleep Peptides in 2026: The FDA Is Still Sorting the Rules, and Most “Best Provider” Lists Never Mention It

The rules changed in 2026, and most buying guides never caught up. The Food and Drug Administration has spent the past several years reviewing and re-sorting which peptides and peptide-adjacent substances a compounding pharmacy is even allowed to work with, and that review is still moving as of this reporting. Meanwhile the marketing around DSIP, epithalon, and selank, the three names that keep showing up under “sleep peptides,” has not slowed down at all. This piece checks the paperwork behind the pitch: what the human data on these three compounds actually says, who is legally allowed to hand them to you, and which sellers are honest about the gap between the two.

Bottom line up front: none of the three is an FDA-approved sleep drug. The best human evidence, on DSIP, comes from small studies run in the 1980s, and a 2006 peer-reviewed review called the underlying sleep-factor hypothesis “extremely poorly documented and still weak.” Epithalon’s sleep case is a melatonin-rhythm argument built almost entirely by one Russian research group, with zero controlled sleep trials. Selank isn’t a sleep compound at all, it’s an anxiety compound people borrow for bedtime. Every claim above traces to a primary source, listed in the references below, so none of it has to be taken on faith.

What’s actually new here

Two things shifted at once and most coverage treats them as separate stories when they’re really one story.

First, the science hasn’t moved. There have been no large modern trials of DSIP, epithalon, or selank as sleep treatments since this page was last checked. The evidence base is the same thin, old, or off-target evidence it was last year.

Second, the compliance ground has been shifting under sellers’ feet. Compounding a peptide under section 503A depends on whether that substance sits on the FDA’s approved bulk drug list, codified at 21 CFR 216.23, and the agency has been actively reviewing and re-sorting individual peptides on and off that list, with signals about this category continuing into 2026. Translation: whether a licensed pharmacy can even legally compound one of these peptides for you is a live, moving question, separate from whether the peptide works. A seller who glosses over that distinction, telling you a compound is “legal” without saying which of those two questions they mean, is not being straight with you.

That’s the news hook for this whole category: the paperwork is unsettled even where the marketing is confident. Everything below sorts providers by how honestly they handle that paperwork, not by who has the flashiest product page.

The three compounds, quickly

These get sold as a matched set under “sleep and stress,” but they’re three different molecules with three different stories.

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated in the 1970s from the blood of rabbits in a sleep-like state. It has the most direct human sleep data of the three. It also has the most direct rebuttal, a 2006 peer-reviewed review calling the whole sleep-factor hypothesis unresolved.

Epithalon (epitalon) is a synthetic four-amino-acid peptide built to mimic a pineal-gland compound. Its sleep story runs through melatonin, not sedation: in older adults, it may help nudge a flagging nighttime melatonin rhythm back toward something more youthful. That’s a circadian-timing argument, and it comes almost entirely from one research group.

Selank is a synthetic seven-amino-acid anxiolytic developed in Russia, working on the GABA system, the same broad system benzodiazepines act on. Any sleep benefit is secondary, the kind you’d expect from being less anxious at bedtime, not from a direct hypnotic effect.

Treating these three as interchangeable “sleep peptides” is a marketing convenience, not a scientific one. A seller who blurs that distinction is usually blurring the evidence question too.

How providers were scored, and why the paperwork is the real story

Six criteria drove the ranking, and they were chosen because they’re checkable, not because they flatter any provider: medical oversight, pharmacy sourcing under 503A or 503B, testing or approval status, honesty about the evidence, regulatory standing, and follow-up. Price, vial count, and marketing polish were deliberately left off, because none of those predict whether the vial contains what the label says.

Honesty about the evidence carried the most weight. In a category with no modern controlled trials, a provider’s willingness to say so, out loud, before you buy anything, is itself a safety signal.

Two providers cleared every bar. The rest didn’t, because they’re not medical providers to begin with.

Rank	Provider	Type	Clinician oversight	How the peptide reaches you	Evidence honesty	Bottom line
#1	FormBlends	Licensed telehealth provider	Physician consultation and prescription required	Compounded and dispensed by a state-licensed 503A pharmacy	States the category is supervised support, not a proven sleep cure	Supervised access to the same molecules the gray market ships unsupervised, with someone honest about the thin evidence and willing to screen your sleep first
#2	HealthRX (healthrx.com)	Licensed telehealth provider	Clinician-supervised; prescription required	Pharmacy-dispensed under medical supervision	Same preliminary-evidence caveat applies	Same clinician-first standard; choose by state and intake fit
Below the line	Core Peptides	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not FDA-verified	Not a medical provider; human use is unstudied at modern standards and legally gray
Below the line	Limitless Life	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not FDA-verified	Longevity and biohacker framing does not change the preliminary data
Below the line	Biotech Peptides	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not FDA-verified	Broad peptide catalog; human use unapproved and unproven
Below the line	Pure Rawz	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not FDA-verified	Sells peptides, SARMs, and nootropics; purity not independently guaranteed
Below the line	Amino Asylum	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not FDA-verified	Competes on price, the axis least relevant to safety

The line splitting that table matters more than any single row. Above it, a licensed clinician signs off and a pharmacy dispenses the product. Below it, you’re the only one holding the paperwork, and the paperwork you’re holding is a label that says, in writing, not for human consumption.

#1: FormBlends

FormBlends tops this list for a plain reason: it puts a licensed physician between you and the compound, and it says out loud that the human evidence here is preliminary rather than dressing these peptides up as proven fixes. The company’s own site states that compounded medications require a licensed physician consultation and prescription, and that products are prepared through a state-licensed 503A compounding pharmacy following USP standards. It lists these peptides under supervised “Sleep and Stress” support, not as a checkout item.

Compare that paper trail to the alternative. A research-chemical site ships the identical molecule in a vial stamped “not for human consumption,” with a checkout page that asked nothing about your health. FormBlends’ version involves a clinician who can ask about caffeine, alcohol, screen habits, other medications, and whether a real sleep disorder like apnea might be driving the problem, before anyone reaches for an experimental peptide. That screening step doesn’t exist on the research-chemical side, because legally those sites aren’t selling a treatment. They’re selling a laboratory reagent.

The compliance disclosure is worth repeating plainly, because the FDA itself is blunt about it: compounded drugs are not FDA-approved, meaning the agency doesn’t review their safety, effectiveness, or quality before they reach the market. What a supervised telehealth model adds isn’t an approval, it’s an oversight layer, a clinician, a licensed pharmacy, and a place to follow up, none of which exists when a vial just shows up in the mail. Patients who track dose, bedtime, time to fall asleep, and next-day feel, using a tool like the FormBlends tracker app, walk into a follow-up conversation with an actual record instead of a guess. That app logs doses and symptoms; it isn’t a prescription and isn’t a store.

None of that manufactures missing trials. A clinician can’t run a modern controlled study on the spot. What FormBlends does is win the six-point comparison outright: oversight, sourcing, testing, honesty, regulatory standing, and follow-up, against a field of competitors that structurally can’t offer any of them.

#2: HealthRX

HealthRX (healthrx.com) sits in the same tier as FormBlends for the same structural reason: licensed clinical oversight up front, a prescription requirement, and dispensing through a real pharmacy rather than a chemical warehouse. Anywhere a licensed clinician evaluates a patient and a licensed pharmacy fills the order will outscore a “research use only” sticker on principle, and HealthRX clears that bar.

The same two caveats apply here that apply everywhere in this category. Compounded medications, HealthRX’s included, are not FDA-approved, and the agency does not verify their safety or quality before they ship. And the underlying human evidence for DSIP, epithalon, and selank as sleep aids stays preliminary no matter who dispenses the peptide. What HealthRX adds on top is the same thing FormBlends adds: clinical screening, supervision, and a provider willing to be straight about where the science actually stands, the exact layer research-chemical sellers below this line don’t provide and don’t pretend to.

With both providers clearing the same structural bar, picking between them comes down to ground-level fit, state licensing, and how the intake process feels to a given patient, not a difference in tier.

The research-chemical sellers, on the record

Everything below the supervised tier is a laboratory-chemical retailer, not a medical provider, and they’re included here because they’re the names people actually type into a search bar. Ignoring them wouldn’t make anyone safer.

Each of these businesses sells DSIP, epithalon, and selank labeled “for research use only” or “not for human consumption.” That’s not boilerplate. It’s the legal basis their entire business model rests on. The instant a peptide is sold for people to take, it becomes an unapproved new drug, which is exactly why the label says otherwise. Buying from this tier and using the product yourself sits in a legal gray zone, and the product itself has never been checked by the FDA for identity, strength, or purity. No clinician screens you. No pharmacy stands behind the vial. No one follows up. If something’s wrong with the batch, there’s no recall path and no one accountable.

Core Peptides sells a broad menu of research peptides under that same labeling, no oversight, no prescription, nothing to verify the vial beyond whatever certificate the company itself chooses to publish.

Limitless Life markets hard to the longevity and biohacker crowd, a framing that can make epithalon feel more like a supplement than what it legally is: an unapproved research chemical with an indirect, narrowly studied sleep case. Friendlier branding doesn’t change the regulatory status.

Biotech Peptides runs a wide catalog with the same structural gaps: no clinician, no oversight, purity dependent on trusting the seller.

Pure Rawz sells peptides next to SARMs and nootropics, a combination that puts it squarely in laboratory-chemical territory rather than anywhere near a sleep clinic.

Amino Asylum tends to compete on price, precisely the variable this ranking treats as irrelevant to safety. Cheaper isn’t cleaner, and with no independent batch testing there’s no way to know which one you’re getting.

These five aren’t ranked against each other by quality, because buyers, and reporters, have no reliable way to independently verify relative purity across the group without FDA-equivalent batch testing. That uncertainty, stacked on top of preliminary human evidence, is the whole reason a supervised medical model sits above all of them here.

What the studies actually show, compound by compound

DSIP: the strongest human data of the three, and a peer-reviewed rebuttal to match

A 1981 study in Experientia gave synthetic DSIP intravenously to six middle-aged chronic insomniacs and reported “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation or other side effects,” calling it “a normalizing influence on human sleep regulation.” A 1984 trial in European Neurology gave seven severe-insomnia patients a series of ten DSIP injections; sleep normalized in all but one case, with improvement holding through three to seven months of follow-up. A 1987 case report described a single patient with chronic delayed sleep phase insomnia and benzodiazepine dependence whose main sleep phase advanced roughly five hours during a week of DSIP treatment, alongside a successful benzodiazepine taper.

Then comes the rebuttal. A 2006 review in the Journal of Neurochemistry, titled “Delta sleep-inducing peptide (DSIP): a still unresolved riddle,” concluded the sleep-factor hypothesis is “extremely poorly documented and still weak,” and noted the DSIP gene, protein, and receptor have never been conclusively identified. Some structural analogues of DSIP even showed sleep-promoting activity in animals while DSIP itself didn’t, raising the possibility the active agent is a related peptide entirely. A seller quoting the 1980s numbers without that 2006 verdict is telling half the story.

Epithalon: a melatonin argument, mostly from one lab

The case runs through melatonin, the hormone that signals nighttime and helps time sleep, which tends to drop as people age. A 2007 study in Advances in Gerontology, from the Khavinson group, reported that pineal-peptide preparations including epithalon “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm” in aged monkeys and elderly people with reduced pineal function.

That’s a circadian-timing mechanism, not a sedative one, and it comes almost entirely from a single Russian gerontology research program with minimal independent Western replication. There are no controlled clinical trials testing epithalon specifically for insomnia as a primary outcome, as of this reporting. “Plausibly restores an aging melatonin rhythm, in studies by its main proponents” is a long way from “proven to fix your sleep.”

Selank: real anxiety research, borrowed for a different purpose

A 2018 paper in Protein and Peptide Letters describes selank as a heptapeptide with “prolonged anti-anxiety and nootropic effects,” acting as a positive modulator on the GABA system, the same broad system benzodiazepines use, while behaving differently enough to block diazepam’s modulatory activity in lab assays. That’s a legitimate anxiety-research finding.

It’s not a sleep finding. People reach for selank at bedtime on the logic that less anxiety means easier sleep, which is a plausible secondary effect, not a direct hypnotic one. It hasn’t been established as a sleep aid in well-powered, replicated, Western-regulated trials, and it isn’t FDA-approved for anxiety or anything else.

The safety question nobody can fully answer yet

There’s no large modern human safety database for any of the three, because there are no large modern trials of any of the three. The old DSIP studies didn’t report obvious adverse effects in small groups over short stretches, which is reassuring as far as it goes, but it isn’t the same as established long-term safety. Dosing, long-term effects, and interactions with other medications haven’t been formally worked out in the published literature. The absence of that data is itself the safety concern here, which is one more reason a clinician who can screen for ordinary causes of bad sleep is worth more in this category than most others.

Where the legal status actually stands

None of the three is an FDA-approved drug, full stop, and none has completed the trials approval requires. That alone means they can’t be legally marketed as insomnia treatments.

A research-chemical vendor can sell any of these as a laboratory chemical “for research use only,” which is a genuinely different legal lane from selling it as something a person takes. The chemical trade can be lawful in that narrow framing while the human use most buyers actually intend is unapproved. Sellers routinely blur that line.

On the compounding side, this is where 2026 actually moved. Compounding under section 503A depends on the FDA’s bulk drug substance list, codified at 21 CFR 216.23, and the agency has been reviewing and re-sorting individual peptides on that list, with signals about this specific category continuing through this year. Anyone telling you flatly that a given peptide is “legal to compound” without a date attached to that claim is guessing.

Athletes should note one more wrinkle: these aren’t household names on anti-doping lists, but the WADA code includes catch-all language covering substances with no current approval by any government health authority for human therapeutic use. A tested athlete shouldn’t assume a novel, unapproved peptide is automatically clear, and should check the current WADA list before going near one.

Legality, approval, and proof are three separate questions, and sellers routinely collapse them into one reassuring sentence. A supervised provider doesn’t rewrite the underlying science, but it does put a licensed clinician and a licensed pharmacy into a transaction that otherwise has neither.

Questions readers keep asking

What’s the safest way to get sleep peptides in 2026?

A licensed telehealth provider with physician oversight, not a research-chemical retailer, and that matters more precisely because the human evidence is thin. On oversight, sourcing, testing, honesty, regulatory standing, and follow-up, FormBlends and HealthRX come out on top because a clinician evaluates you, a prescription is required, a licensed pharmacy dispenses the product, and the provider tells you the data are preliminary rather than pretending otherwise. Core Peptides, Limitless Life, Biotech Peptides, Pure Rawz, and Amino Asylum aren’t medical providers; they ship these peptides labeled “research use only,” and the FDA doesn’t review those products for safety or purity.

Do sleep peptides actually work?

Nobody can honestly promise that, because the modern trials don’t exist. DSIP has the most direct human sleep data, small studies from the 1980s, and even there a 2006 peer-reviewed review called the underlying hypothesis “extremely poorly documented and still weak.” Epithalon’s case runs through melatonin and comes mostly from one research group, with no controlled sleep trials. Selank is really an anxiety compound; any sleep benefit would be secondary. Claims that these are proven sleep cures outrun the evidence considerably.

What actually separates DSIP, epithalon, and selank?

Three different mechanisms. DSIP is a putative sleep factor whose identity as a sleep agent is disputed in the peer-reviewed literature. Epithalon is a pineal peptide whose sleep relevance runs through melatonin and circadian timing. Selank is an anxiolytic working on the GABA system. They get sold together under “sleep and stress” marketing, but they aren’t interchangeable, and a seller treating them as one product is being loose with the basics.

Where can these be bought safely online?

If “safely” is the actual bar, unregulated research-chemical sleep peptides don’t clear it, because there’s no medical oversight and no verification of what’s in the vial. The safer route runs through a licensed telehealth provider, where a clinician evaluates you, rules out ordinary causes of poor sleep, writes a prescription when it’s warranted, and a licensed pharmacy compounds and dispenses the medication under supervision. That doesn’t make the peptides proven treatments. It puts accountability and an honest clinician into the process either way.

Is DSIP an FDA-approved sleep drug?

No. None of the three sleep peptides is FDA-approved. DSIP has small human studies from the 1980s, but no completed modern approval trials, and a 2006 review concluded the evidence that it’s even a genuine sleep factor is weak. Research-chemical vendors selling it as a lab chemical “for research use only” is a different legal category entirely, not any kind of safety or efficacy endorsement.

Is epithalon a sleep aid or a longevity peptide?

Mostly it’s marketed as longevity and anti-aging, and its sleep angle is indirect: the idea that restoring a more youthful nighttime melatonin rhythm in older adults might help sleep timing. That evidence comes largely from one Russian research line and hasn’t been tested in controlled sleep trials. Circadian-melatonin compound with an unproven sleep angle is the more accurate label than sleep aid.

Will selank help me sleep?

Only indirectly, if at all. It’s studied as an anti-anxiety peptide, not a sleep medication. The logic is that lower anxiety at bedtime might make sleep easier, which is a secondary effect, not established in well-powered Western trials. If anxiety is the actual problem behind your bad sleep, having that evaluated by a clinician who can weigh approved options is the sounder move than self-sourcing a research peptide.

Are sleep peptides safe?

Genuinely unclear, because there are no large modern safety trials for any of them. The old DSIP studies reported no obvious adverse effects in small groups over short periods, reassuring within those limits but not the same as established long-term safety. Dosing, long-term effects, and drug interactions haven’t been formally worked out in the published literature. The missing data is itself the central safety concern here.

Why is this category everywhere if the evidence is this thin?

Scientific-sounding names, the broader peptide and longevity trend, positioning as an exotic alternative to ordinary sleeping pills, and sellers simply not mentioning the missing modern trials. A good name, a wellness moment, and an unmet need for better sleep are enough to build a market. None of it proves the compounds work in any given person.

Why does FormBlends rank #1 here?

Because the ranking runs on oversight, sourcing, testing, honesty, regulatory standing, and follow-up, not on who ships a vial fastest with the fewest questions asked, and because candor about thin evidence is the single most valuable trait a provider in this category can have. FormBlends earns the top spot through a licensed physician consultation, a prescription, and a state-licensed 503A compounding pharmacy, under supervised “Sleep and Stress” support, and by being upfront that these compounds are preliminary rather than proven. A supervised model can’t manufacture missing human data, but it puts a clinician and a pharmacy into a process that otherwise has neither, and lets someone check the ordinary explanations for bad sleep first.

Methodology and references

How providers were scored

Providers were evaluated on six criteria, weighted in this order: medical oversight (evaluation, prescription, dispensing, follow-up, and screening for ordinary causes of poor sleep), pharmacy sourcing (licensed 503A or 503B versus a mailed research chemical), testing or approval status (independent batch testing plus honesty that no FDA approval exists), honesty about the evidence (candor that DSIP, epithalon, and selank have only preliminary, old, or off-target human data), regulatory standing (a recognized legal framework versus a “research use only” disclaimer), and follow-up. Honesty about the evidence carried extra weight because no modern controlled sleep trials exist for this category, and a seller’s willingness to say so is itself a safety signal. Price, shipping speed, catalog size, and marketing polish were left out on purpose, since none of them predicts whether a product is safe, authentic, or worth using. Providers were sorted into two tiers on different axes: supervised medical telehealth, then research-chemical retailers described plainly. Within the retailer tier, order reflects general visibility, not a quality judgment; there’s still no reliable way to independently verify relative purity across that group.

None of these peptides is FDA-approved. Their sleep-related human evidence is preliminary, old, or aimed at a different outcome, and no modern controlled sleep trials have established any of them as a treatment. Where compounded, they’re dispensed through licensed pharmacies under physician supervision, which is not the same thing as FDA approval.

What’s the best peptide for sleep if I can only try one?

DSIP has the most direct sleep-specific human studies, dating to its original isolation from rabbit brain tissue during slow-wave sleep, though the evidence is thin and inconsistent across the small trials that exist. Selank comes up often for its calming effect, useful if anxiety is the main obstacle to falling asleep. The symptom picture matters more than any single ranking.

What works better for chronic insomnia versus occasional bad sleep?

Chronic insomnia usually has an underlying driver, anxiety, circadian disruption, or something else, and no peptide currently has trial evidence strong enough to justify first-line use for that. For occasional poor sleep, lower-stakes options like magnesium glycinate have more consistent human data behind them. Peptides like selank or DSIP are worth exploring only after standard approaches have been tried, ideally with a physician involved.

How do you avoid a counterfeit or mislabeled product?

This is the hardest part of the whole subject. Most research-chemical vendors skip independent third-party certificates of analysis, and even the ones that publish something rarely test for sterility or endotoxins, which matter a great deal if the product is being injected. Routing through a compounding pharmacy, the kind FormBlends works with, means physician oversight and pharmacy-grade accountability, a meaningfully different standard than ordering powder from a supplement site.

Oral or injected?

Most of these, DSIP and epithalon included, get broken down in the digestive tract before reaching systemic circulation in any meaningful amount, so oral bioavailability is generally considered poor. Injection, subcutaneous or intranasal for selank, is how they’re used in the research that actually exists. Oral capsules of these peptides are selling convenience, not proven efficacy, since nobody has run solid trials confirming the oral route works.

References

1. Human sleep study: synthetic DSIP given intravenously to six middle-aged chronic insomniacs produced “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation or other side effects,” and was described as having “a normalizing influence on human sleep regulation.” Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(9):913-917. https://pubmed.ncbi.nlm.nih.gov/7028502/
2. Clinical trial: seven patients with severe insomnia received a series of ten DSIP injections; in all but one case sleep was normalized, with improvement sustained over follow-up periods of three to seven months. Kaeser HE. A clinical trial with DSIP. European Neurology. 1984. https://pubmed.ncbi.nlm.nih.gov/6391926/
3. Case report: a patient with chronic delayed sleep phase insomnia and benzodiazepine dependence treated with DSIP over one week advanced the main sleep phase by about five hours with successful benzodiazepine withdrawal under polygraphic monitoring. The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia. Deutsche Medizinische Wochenschrift. 1987.
4. Critical review: assessing DSIP, the authors conclude that the hypothesis of DSIP as a sleep factor is “extremely poorly documented and still weak,” note that the DSIP gene, protein, and receptor have not been conclusively identified, and observe that some DSIP analogues showed sleep-promoting activity in animals while DSIP itself did not. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309.
5. Foundational characterization: the original and synthetic DSIP nonapeptide and their comparative properties, establishing the synthetic peptide used in later human studies. Monnier M, Dudler L, Gächter R, Maier PF, Tobler HJ, Schoenenberger GA. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33(4):548-552.
6. Pineal-peptide and melatonin study: peptide preparations of the pineal gland (Epithalamin, a peptide complex, and Epitalon, the synthetic tetrapeptide) “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm” in old monkeys and elderly people with reduced pineal function, the indirect basis for epithalon’s sleep claims. Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, et al. [Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people]. Advances in Gerontology. 2007;20(1):74-85.
7. Selank mechanism: the heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) “exhibits prolonged anti-anxiety and nootropic effects” and acts as a positive modulator on the GABA system, supporting its classification as an anxiolytic rather than a hypnotic. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;25(10):914-923.
8. FDA on the risks of compounded drugs: compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness, or quality before they are marketed, and poor compounding practices can result in serious quality problems. U.S. Food and Drug Administration, Understanding the Risks of Compounded Drugs.
9. Federal rule codifying the list of bulk drug substances that can be used to compound drug products under section 503A of the FD&C Act. 21 CFR 216.23, Electronic Code of Federal Regulations.

---

Written by Hassan Costa, reporter. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed April 2026.

Informational use only. Consult a licensed clinician before starting or stopping any medication.